The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2193-1801

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer ; volume:5 ; number:1 ; day:3 ; month:8 ; year:2016 ; pages:1-7 ; date:12.2016
SpringerPlus ; 5, Heft 1 (3.8.2016), 1-7, 12.2016

Creator: Yufen, Xu

Contributor: Binbin, Song
Wenyu, Chen
Jialiang, Liu
Xinmei, Yang
SpringerLink (Online service)

DOI: 10.1186/s40064-016-2873-2

URN: urn:nbn:de:1111-201608049598

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:48 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Yufen, Xu
Binbin, Song
Wenyu, Chen
Jialiang, Liu
Xinmei, Yang
SpringerLink (Online service)

Other Objects (12)

Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis

Leptomeningeal metastases from solid tumours

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Leptomeningeal Metastases: New Opportunities in the Modern Era

Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis

Leptomeningeal metastases from solid tumours

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Leptomeningeal Metastases: New Opportunities in the Modern Era

Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis

Leptomeningeal metastases from solid tumours

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Leptomeningeal Metastases: New Opportunities in the Modern Era

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis

Leptomeningeal metastases from solid tumours

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Leptomeningeal Metastases: New Opportunities in the Modern Era

Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis

Leptomeningeal metastases from solid tumours

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Leptomeningeal Metastases: New Opportunities in the Modern Era

Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis

Leptomeningeal metastases from solid tumours

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Leptomeningeal Metastases: New Opportunities in the Modern Era

Related objects

Reset password